An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders
NCT01064973
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
32
Enrollment
INDUSTRY
Sponsor class
Stopped
all active subjects were rolled into study 209AS209/NCT01706523
Conditions
Autism Spectrum Disorders
Interventions
DRUG:
arbaclofen
Sponsor
Seaside Therapeutics, Inc.